The studies using breast cancer cell lines overexpressing HER2 provide us with the result that GEF is selective for EGFR in vitro, but at the same time, in vivo, it reduces the basal phosphorylation of EGFR1, EGFR2, and EGFR3. Here, ERBB2 is linked to breast carcinoma.